Novo Nordisk buys Prothena’s heart therapy drug

Novo Nordisk A/S announced on Monday that it has reached an agreement to acquire Prothena Corporation plc’s ATTR amyloidosis programme.

Under the terms of the agreement, Prothena is eligible to r…